Attached files
| file | filename |
|---|---|
| EX-10.16 - EX-10.16 - Karyopharm Therapeutics Inc. | d282276dex1016.htm |
| EX-32.1 - EX-32.1 - Karyopharm Therapeutics Inc. | d282276dex321.htm |
| EX-31.2 - EX-31.2 - Karyopharm Therapeutics Inc. | d282276dex312.htm |
| EX-31.1 - EX-31.1 - Karyopharm Therapeutics Inc. | d282276dex311.htm |
| EX-23.1 - EX-23.1 - Karyopharm Therapeutics Inc. | d282276dex231.htm |
| EX-21.1 - EX-21.1 - Karyopharm Therapeutics Inc. | d282276dex211.htm |
| 10-K - FORM 10-K - Karyopharm Therapeutics Inc. | d282276d10k.htm |
Exhibit 12.1
STATEMENT REGARDING COMPUTATION OF CONSOLIDATED RATIOS OF EARNINGS TO FIXED CHARGES AND RATIOS OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS
| Fiscal Year Ended December 31, | ||||||||||||||||||||
| 2016 | 2015 | 2014 | 2013 | 2012 | ||||||||||||||||
| Loss from operations |
(110,732 | ) | (119,076 | ) | (75,846 | ) | (33,950 | ) | (15,890 | ) | ||||||||||
| add: Fixed charges (see below) |
383 | 344 | 173 | 58 | 53 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Pre-tax loss from continuing operations plus fixed charges |
(110,349 | ) | (118,732 | ) | (75,673 | ) | (33,892 | ) | (15,837 | ) | ||||||||||
| Fixed charges: |
||||||||||||||||||||
| Interest expense on indebtedness |
— | — | — | — | — | |||||||||||||||
| Interest expense on portion of rent expense representative of interest |
383 | 344 | 173 | 58 | 53 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Total fixed charges |
383 | 344 | 173 | 58 | 53 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Ratio of earnings to fixed charges |
— | — | — | — | — | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Deficiency of earnings available to cover fixed charges |
(110,732 | ) | (119,076 | ) | (75,846 | ) | (33,950 | ) | (15,890 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
$ in thousands